Reaction

Histoplasmosis Disseminated reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,538 reports · 50 co-occurring drugs

As of the last recalculation, Histoplasmosis Disseminated appears in 1,538 FAERS reports alongside 50 co-occurring drug terms. The strongest observed disproportionality signal is ITRACONAZOLE (PRR 102.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Itraconazole84102.9103.6
Amphotericin B5865.165.4
Mycophenilic Acid9263.864.1
Tacrolimus Ointment 0.1%36050.850.9
Tacrolimus Extended-Release Capsules36050.650.8
Tacrolimus37742.842.9
Mycophenolate Mofetil32941.441.5
Mycophenolate Mofetil Hydrochloride32941.441.5
Mycophenolic Acid9241.341.4
Adalimumab-Fkjp11536.236.3
Adalimumab-Aaty11535.535.5
Adalimumab-Adaz11632.132.2
Mercaptopurine3830.430.4
Prednisone60726.326.4
Infliximab33326.126.1
Anti-Thymocyte Globulin (Rabbit)1525.425.4
Efavirenz1720.920.9
Azathioprine12420.620.7
Sirolimus1717.317.3
Methotrexate40117.117.1
Erlotinib1216.916.9
Cefepime1716.216.2
Methotrexate Sodium41715.615.6
Hydroxychloroquine7614.414.5
Cefepime Hydrochloride1714.414.4
Abacavir Sulfate1014.014.0
Basiliximab1213.913.9
Moxifloxacin1413.613.6
Atovaquone813.513.5
Obinutuzumab1613.313.3
Erlotinib Hydrochloride1213.113.1
Micafungin Sodium812.812.8
Piperacillin And Tazobactam1212.812.8
Alemtuzumab1812.712.7
Vancomycin4911.811.8
Minocycline1011.711.7
Vancomycin Hydrochloride5211.011.0
Piperacillin Sodium,Tazobactam Sodium2110.810.9
Ganciclovir810.610.6
Ganciclovir Sodium810.310.3
Lamivudine2310.210.2
Baricitinib79.99.9
Lamivudine Oral189.79.7
Ceftriaxone239.69.6
Remdesivir99.29.2
Posaconazole Delayed-Release78.78.7
Ceftriaxone Sodium238.28.2
Voriconazole Injection138.28.2
Oseltamivir46.86.8
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate53.73.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.